2024
ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.
Petrylak D, McKean M, Lang J, Gao X, Dreicer R, Geynisman D, Stewart T, Gandhi M, Appleman L, Dorff T, Chatta G, Tutrone R, De La Cerda J, Berghorn E, Gong J, Yu T, Dominy E, Chan E, Shore N. ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study. Journal Of Clinical Oncology 2024, 42: 5011-5011. DOI: 10.1200/jco.2024.42.16_suppl.5011.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerTreatment-related adverse eventsAR-LBD mutationsPhase 1/2 studyClinical activityProstate cancerAndrogen receptorAdverse eventsMetastatic castration-resistant prostate cancer treatmentProgressive metastatic castration-resistant prostate cancerPhase 1 dose-escalation portionDisease progressionTreatment-emergent adverse eventsCastration-resistant prostate cancerResistant to available therapiesAssociated with poor outcomesDose-limiting toxicityAndrogen deprivation therapyAdvanced prostate cancerIncreased blood creatinineWild-type ARSubgroup of patientsDose-dependent increaseDeprivation therapyPretreated patients
2020
Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial
Drakaki A, Kirby C, van der Heijden M, Petrylak D, Powles T, N. K, Fléchon A, Necchi A, Géczi L, Lee J, Gakis G, Bracarda S, Chowdhury S, Lin C, Keizman D, Vaishampayan U, Zimmermann A, Bell-McGuinn K, Castellano D. Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial. Bladder Cancer 2020, 6: 43-52. DOI: 10.3233/blc-190252.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsProgression-free survivalOverall response ratePrior immune checkpoint inhibitorsUrothelial carcinomaCheckpoint inhibitorsPlatinum-refractory metastatic urothelial carcinomaUnstratified Cox proportional hazards modelMedian progression-free survivalPlatinum-refractory urothelial carcinomaImproved progression-free survivalPre-specified subgroup analysisCox proportional hazards modelMetastatic UC patientsMetastatic urothelial carcinomaAdvanced urothelial carcinomaKaplan-Meier methodSubgroup of patientsProportional hazards modelICI therapyUC patientsDocetaxel armMost patientsAdverse eventsARM patients